Literature DB >> 17931120

Protection from infection with severe acute respiratory syndrome coronavirus in a Chinese hamster model by equine neutralizing F(ab')2.

Deyan Luo1, Bing Ni, Guangyu Zhao, Zhengcai Jia, Lili Zhou, Marek Pacal, Liangyan Zhang, Songle Zhang, Li Xing, Zhihua Lin, Li Wang, Jintao Li, Yunfei Liang, Xinfu Shi, Tingting Zhao, Liyun Zou, Yuzhang Wu, Xiliang Wang.   

Abstract

To warrant potential clinical testing, the equine anti-severe acute respiratory syndrome coronavirus (SARS-CoV) F(ab')(2) requires evaluation in as many animal models as possible. In this study, we established a new animal model, the Chinese hamster, susceptible to SARS-CoV infection. SARS-CoV could propagate effectively and sustain high levels for 1 wk in animal lungs. All animals were protected from SARS-CoV infection in preventive settings. Further, when used therapeutically this antibody led to an approximately 4-log(10) decrease in viral burden in infected animal lungs. The pathological changes in lungs correlated closely with the dose of antibody administered. The excellent preventive and therapeutic roles of equine anti-SARS-CoV F(ab')(2) in several animal models, including the novel Chinese hamster model described in this study, have provided exciting data concerning its potential clinical study.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17931120     DOI: 10.1089/vim.2007.0038

Source DB:  PubMed          Journal:  Viral Immunol        ISSN: 0882-8245            Impact factor:   2.257


  11 in total

1.  Comparison of multiple vaccine vectors in a single heterologous prime-boost trial.

Authors:  Brice Barefoot; Natalie J Thornburg; Daniel H Barouch; Jae-Sung Yu; Christopher Sample; Robert E Johnston; Hua Xin Liao; Thomas B Kepler; Barton F Haynes; Elizabeth Ramsburg
Journal:  Vaccine       Date:  2008-09-20       Impact factor: 3.641

2.  Recent developments in anti-severe acute respiratory syndrome coronavirus chemotherapy.

Authors:  Dale L Barnard; Yohichi Kumaki
Journal:  Future Virol       Date:  2011-05       Impact factor: 1.831

3.  Development and characterization of two equine formulations towards SARS-CoV-2 proteins for the potential treatment of COVID-19.

Authors:  Guillermo León; María Herrera; Mariángela Vargas; Mauricio Arguedas; Andrés Sánchez; Álvaro Segura; Aarón Gómez; Gabriela Solano; Eugenia Corrales-Aguilar; Kenneth Risner; Aarthi Narayanan; Charles Bailey; Mauren Villalta; Andrés Hernández; Adriana Sánchez; Daniel Cordero; Daniela Solano; Gina Durán; Eduardo Segura; Maykel Cerdas; Deibid Umaña; Edwin Moscoso; Ricardo Estrada; Jairo Gutiérrez; Marcos Méndez; Ana Cecilia Castillo; Laura Sánchez; Ronald Sánchez; José María Gutiérrez; Cecilia Díaz; Alberto Alape
Journal:  Sci Rep       Date:  2021-05-10       Impact factor: 4.379

4.  Equine Immunoglobulin and Equine Neutralizing F(ab')₂ Protect Mice from West Nile Virus Infection.

Authors:  Jiannan Cui; Yongkun Zhao; Hualei Wang; Boning Qiu; Zengguo Cao; Qian Li; Yanbo Zhang; Feihu Yan; Hongli Jin; Tiecheng Wang; Weiyang Sun; Na Feng; Yuwei Gao; Jing Sun; Yanqun Wang; Stanley Perlman; Jincun Zhao; Songtao Yang; Xianzhu Xia
Journal:  Viruses       Date:  2016-12-18       Impact factor: 5.048

Review 5.  A decade after SARS: strategies for controlling emerging coronaviruses.

Authors:  Rachel L Graham; Eric F Donaldson; Ralph S Baric
Journal:  Nat Rev Microbiol       Date:  2013-11-11       Impact factor: 60.633

Review 6.  From SARS to MERS, Thrusting Coronaviruses into the Spotlight.

Authors:  Zhiqi Song; Yanfeng Xu; Linlin Bao; Ling Zhang; Pin Yu; Yajin Qu; Hua Zhu; Wenjie Zhao; Yunlin Han; Chuan Qin
Journal:  Viruses       Date:  2019-01-14       Impact factor: 5.048

7.  Phagocytic cells contribute to the antibody-mediated elimination of pulmonary-infected SARS coronavirus.

Authors:  Fumihiko Yasui; Michinori Kohara; Masahiro Kitabatake; Tetsu Nishiwaki; Hideki Fujii; Chise Tateno; Misako Yoneda; Kouichi Morita; Kouji Matsushima; Shigeo Koyasu; Chieko Kai
Journal:  Virology       Date:  2014-03-04       Impact factor: 3.616

8.  Protection from infection with influenza A H7N9 virus in a mouse model by equine neutralizing F(ab')2.

Authors:  Zhongpeng Zhao; Chuanbo Fan; Yueqiang Duan; Liangyan Zhang; Min Li; Xiaolan Yang; Ruisheng Li; Penghui Yang; Xiliang Wang
Journal:  Int Immunopharmacol       Date:  2014-09-02       Impact factor: 4.932

9.  Evaluation of the safety, immunogenicity and pharmacokinetics of equine anti-SARS-CoV F(ab')(2) in macaque.

Authors:  Yunsheng Xu; Zhengcai Jia; Liyun Zhou; Li Wang; Jintao Li; Yunfei Liang; Tingting Zhao; Bing Ni; Yuzhang Wu
Journal:  Int Immunopharmacol       Date:  2007-10-04       Impact factor: 4.932

Review 10.  Benefits of using heterologous polyclonal antibodies and potential applications to new and undertreated infectious pathogens.

Authors:  Rashmi Dixit; Jenny Herz; Richard Dalton; Robert Booy
Journal:  Vaccine       Date:  2016-01-20       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.